



Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation Process

Paul A. Harris, PhD; Consuelo H. Wilkins, MD, MSCI; Karen Lane, CMA; Gordon R. Bernard, MD; Jonathan D. Casey, MD; Daniel E. Ford, MD; Salina P. Waddy, MD; Ken L. Wiley Jr, PhD; Terri L. Edwards, RN; Nichol McBee, MPH; Dixie D. Thompson, BSN, RN; Mary Stroud, RN; Emily Serdoz, MPH; Nan Kennedy, MLAS; Sarah J. Nelson, MS; Michelle Jones, MEd; Lindsay M. Eyzaguirre, MS; Leslie R. Boone, MPH; Jessica Baird, PhD; Colleen Lawrence, PhD; Elizabeth Holthouse, PhD; Sarah K. Cook, MPH; Maeve Tischbein, PhD; Natalya Amrine, AAS; Tiffany Chen, MPH; Jodie Cohen, MA; LaShondra Deyampert, MPH; Natalie Dilts, MPH; Delicia Burts, MPH; Amna Baig, MPH; Joseph Christodoulou, MPH; Mariela Rodriguez, MPH; Edgar R. Miller III, MD, PhD; James F. Casella, MD; W. Andrew Mould, MPH; J. Michael Dean, MD; Daniel K. Benjamin Jr, MD, PhD; Harry P. Selker, MD, MSPH; Marisha E. Palm, MSc, PhD; Lori Poole, PMP; Jeri S. Burr, MS, RN; Sara Hassani, MD, MHS, MSCR; Angeline Nanni, MBA; Meghan Hildreth, MS; Daniel F. Hanley, MD

Introduction

The National Institutes of Health's National Center for Advancing Translational Sciences established the Trial Innovation Network (TIN) as national infrastructure to address multicenter trial barriers and offer investigators access to a scientific consultative process, clinical trial and disease experts, and methods across the trial life cycle.^{1,2} The TIN initial consultation process provides researchers with resources and recommendations to address complex aspects of planning and conducting more informative clinical trials; data-driven solutions for site identification, representative recruitment, and retention planning; data management; and regulatory compliance.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Methods

This qualitative study reports on TIN Initial Consultations from proposals submitted to the TIN from October 26, 2016, until June 1, 2024. This study followed the Standards for Reporting Qualitative Research (SRQR) reporting guideline and did not involve human participants research; therefore, as set out in the Federal Policy for the Protection of Human Subjects, codified at 45 CFR 46.102, Institutional review board (IRB) approval was not required.

A proposal requesting a TIN consultation for a planned or current multicenter study is submitted by the study investigator via the TIN's website portal. The proposal is reviewed within 5 days, aligned with a Trial Innovation Center (TIC) and/or Recruitment Innovation Center (RIC)³ with the capacity and pertinent expertise (**Figure 1**). The assigned TIC or RIC team convenes an introductory call with the study investigator to ensure that initial requests for resources, such as single IRB, site expression of interest, electronic health records-based recruitment, and/or recruitment and retention planning and materials, are appropriate and to determine whether additional, nonrequested resources are advantageous. Domain experts with prior trial experience in relevant therapeutic, methodological, and population areas are then identified. Next, a kick-off call is scheduled with the investigator, identified experts, and applicable resource leads to discuss topics such as the scientific premise, expected outcomes, and recruitment and retention plan. Additional, topic-specific calls are scheduled as needed. A final wrap-up call summarizes the guidance given and finalizes TIN resource provision. Based on an assessment of the project's needs and potential benefits from further support, the TIC/RIC team may provide a recommendations report, recommendations plus resources, or a comprehensive consultation. A summary of completed initial consultations is presented to a TIN governance committee—the proposal assessment team (PAT)—comprising leadership from each of the TICs, the RIC, and NCATS. The recommendation for a comprehensive consultation requires an active discussion and affirmative vote from the PAT to proceed. A planned publication will describe the Comprehensive Consultation process.


Open Access. This is an open access article distributed under the terms of the CC-BY License.

Results

From October 26, 2016, until June 1, 2024, 445 proposals were submitted to the TIN for consultation, a median (IQR) of 46 (29) proposals per year. Thirteen inaugural proposals received in 2016 were developed as use cases to organize TIN processes, with 7 proposals supported as demonstration projects (54%) and 6 as pilot studies (46%). The TIN initial consultation process then started in earnest, and through June 1, 2024, a total of 432 proposals (97%) were assigned to a TIC/RIC for an initial consultation upon receipt, with all receiving a recommendations report. A total of 115 proposals (26.6%) received the recommendations report only, 189 requested and received targeted TIN resources (43.7%), 75 moved to a comprehensive consultation (17.4%), and 53 were either still active or on hold as of June 1, 2024 (12.3%) (Figure 2).


Starting in 2019, the TIN began sending clinical trial teams a 3-question satisfaction survey to provide feedback to the TIN, anonymously if desired (Figure 2). A net promoter score (NPS)⁴ is calculated across all completed survey responses for each question. Between 2019 and 2024, investigator ratings from 168 completed surveys resulted in an NPS rating of world class satisfaction with the TIN initial consultation process.

Figure 1. Schematic of Initial Consultation Process



PAT, Proposal Assessment Team; PI, principal investigator; RIC, Recruitment Innovation Center; TIC, Trial Innovation Center; TIN, Trial Innovation Network.

Figure 2. Trial Innovation Network (TIN) Initial Consultation Metrics



IRB indicates institutional review board; RIC, Recruitment Innovation Center; TIC, Trial Innovation Center.

^a Net promoter score (NPS) = % promoters – % detractors. Individual NPSs were averaged across all 3 questions for a total mean NPS. The NPS is interpreted as good (ie, any positive score above 0), excellent (ie, a score of 50-69), or world class (a score of ≥70). NPS scores are aggregated across all TICs/RIC and by individual TICs/RIC in instances where the principal investigator voluntarily self-identifies as part of the survey.

Discussion

The TIN has built infrastructure and resources to help investigators improve and accelerate multisite clinical trials, starting with the initial consultation process. Over time, TIN leadership has identified classes of issues that impede timely completion of clinical trials, and developed innovations—tools, methods, and resources—to address them.^{5,6} US-based investigators who are proposing, planning, or conducting a multicenter study, with any type of funding or in any discipline, can request a consultation through the TIN website portal. Our assessment is limited by the absence of a comparable consultation network for benchmarking. TIN consultations are provided at no cost to investigators.

ARTICLE INFORMATION

Accepted for Publication: March 27, 2025.

Published: May 29, 2025. doi:10.1001/jamanetworkopen.2025.12926

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2025 Harris PA et al. JAMA Network Open.

Corresponding Author: Paul A. Harris, PhD, Professor, Department of Biomedical Informatics, Director, Office of Research Informatics, Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center (VUMC), 2525 West End Ave, Nashville, TN 37203 (paul.a.harris@vumc.org).

Author Affiliations: Vanderbilt Institute for Clinical and Translational Research, Nashville, Tennessee (Harris, Wilkins, Bernard, Casey, Edwards, Stroud, Serdoz, Kennedy, Nelson, Jones, Boone, Lawrence, Cook, Tischbein, Amrine, Chen, Cohen, Deyampert, Dilts, Burts, Baig, Christodoulou, Rodriguez); Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee (Harris); Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (Wilkins, Bernard, Casey); Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee (Wilkins); Johns Hopkins University School of Medicine, Baltimore, Maryland (Lane, Ford, McBee, Eyzaguirre, Baird, Holthouse, Miller, Casella, Mould, Hanley); Duke Clinical Research Institute, Durham, North Carolina (Poole); Johns Hopkins Institute for Clinical and Translational Research, Baltimore, Maryland (Ford, Casella, Burr, Nanni, Hildreth, Hanley); National Center for Advancing Translational Sciences, Bethesda, Maryland (Waddy, Wiley, Hassani); University of Utah Health, Salt Lake City (Thompson, Dean); Utah Clinical and Translational Science Institute, Salt Lake City (Thompson); Duke University School of Medicine, Durham, North Carolina (Benjamin); Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts (Selker, Palm); Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts (Selker, Palm).

Author Contributions: Dr Harris had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Harris, Wilkins, Lane, Bernard, Casey, Ford, Wiley, McBee, Thompson, Serdoz, Eyzaguirre, Baird, Lawrence, Mould, Dean, Benjamin, Palm, Poole, Burr, Nanni, Hanley.

Acquisition, analysis, or interpretation of data: Harris, Wilkins, Bernard, Ford, Waddy, Edwards, McBee, Stroud, Kennedy, Nelson, Jones, Eyzaguirre, Boone, Holthouse, Cook, Tischbein, Amrine, Chen, Cohen, Deyampert, Dilts, Burts, Baig, Christodoulou, Rodriguez, Miller, Casella, Mould, Dean, Selker, Palm, Burr, Hassani, Hildreth, Hanley.

Drafting of the manuscript: Harris, Lane, Edwards, McBee, Thompson, Stroud, Serdoz, Kennedy, Nelson, Eyzaguirre, Boone, Burts, Christodoulou, Poole, Nanni.

Critical review of the manuscript for important intellectual content: Harris, Wilkins, Lane, Bernard, Casey, Ford, Waddy, Wiley, McBee, Thompson, Kennedy, Nelson, Jones, Eyzaguirre, Boone, Baird, Lawrence, Holthouse, Cook, Tischbein, Amrine, Chen, Cohen, Deyampert, Dilts, Baig, Rodriguez, Miller, Casella, Mould, Dean, Benjamin, Selker, Palm, Burr, Hassani, Nanni, Hildreth, Hanley.

Obtained funding: Harris, Lane, Bernard, Ford, Dean, Benjamin, Hanley.

Administrative, technical, or material support: Harris, Wilkins, Edwards, McBee, Thompson, Stroud, Serdoz, Kennedy, Nelson, Jones, Eyzaguirre, Boone, Baird, Lawrence, Holthouse, Cook, Tischbein, Amrine, Chen, Cohen, Dilts, Burts, Baig, Christodoulou, Rodriguez, Miller, Casella, Dean, Palm, Poole, Burr, Hildreth.

Supervision: Harris, Wilkins, Lane, Bernard, Ford, Kennedy, Nelson, Cohen, Burts, Baig, Christodoulou, Dean, Burr, Hanley.

Conflict of Interest Disclosures: Dr Wilkins reported receiving grants from Patient Centered Outcomes Research Institute during the conduct of the study. Dr Casey reported receiving a travel grant from Fisher and Paykel Travel to speak at a conference outside the submitted work. Dr Ford reported receiving grants from Johns Hopkins University School of Medicine during the conduct of the study. Dr Casella reported grants from the US Centers for Disease Control and Prevention, Maternal and Child Health Bureau, and the state of Maryland and having a patent for a panel of biomarkers for detection of brain injury with royalties paid from ImmunArray and a patent for aptamers for treatment of sickle cell disease issued outside the submitted work. Dr Benjamin reported receiving personal fees from AbbVie, PPD, and Syneos Health outside the submitted work. Dr Hanley reported receiving stock options from Epiwatch during the conduct of the study. No other disclosures were reported.

Funding/Support: This work is supported by the National Institutes of Health Center for Advancing Translational Sciences (NCATS) and the National Institute on Aging, in support of the Trial Innovation Network under grant numbers U24TR004432 (VUMC RIC), U24TR004437 (VUMC TIC), and U24TR004440 (JHU TIC).

Role of the Funder/Sponsor: The design and conduct of the study was a cooperative endeavor with NCATS program officers who collectively helped define and refine trial-based operations, create the Initial Consultation model, and design the governance structure. NCATS did not have a role in the collection, management, analysis, or

interpretation of data. NCATS officers assisted with preparation, review, approval of the manuscript, and the decision to submit the manuscript for publication.

Data Sharing Statement: See the [Supplement](#).

Additional Contributions: We acknowledge and are especially grateful for contributions of previous Trial Innovation Network members from Duke University, University of Utah, and Tufts University who helped develop the Initial Consultation structure. We are also grateful for the partnership and engagement of the Hub Liaison teams from across the Clinical and Translational Science Award program hubs. We acknowledge and thank the National Center for Advancing Translational Sciences program staff, principal investigator (PI) advisors, Clinical and Translational Science Award PIs, and investigative teams that have collaborated with the Trial Innovation Network. We acknowledge with appreciation the Vanderbilt University Medical Center Recruitment Innovation Center Community Advisory Board for their many contributions to the work of the TIN.

REFERENCES

1. Bernard GR, Harris PA, Pulley JM, et al. A collaborative, academic approach to optimizing the national clinical research infrastructure: the first year of the Trial Innovation Network. *J Clin Transl Sci*. 2018;2(4):187-192. doi:10.1017/cts.2018.319
2. Harris PA, Dunsmore SE, Atkinson JC, et al; Trial Innovation Network. Leveraging the expertise of the CTSA program to increase the impact and efficiency of clinical trials. *JAMA Netw Open*. 2023;6(10):e2336470. doi:10.1001/jamanetworkopen.2023.36470
3. Wilkins CH, Edwards TL, Stroud M, et al. The recruitment innovation center: developing novel, person-centered strategies for clinical trial recruitment and retention. *J Clin Transl Sci*. 2021;5(1):e194. doi:10.1017/cts.2021.841
4. What is net promoter. Net Promoter. Accessed July 2, 2024. <https://www.netpromoter.com/know/>
5. Lane K, Palm ME, Marion E, et al. Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. *J Clin Transl Sci*. 2023;7(1):e131. doi:10.1017/cts.2023.560
6. Palm ME, Edwards TL, Wieber C, et al. Development, implementation, and dissemination of operational innovations across the trial innovation network. *J Clin Transl Sci*. 2023;7(1):e251. doi:10.1017/cts.2023.658

SUPPLEMENT.

Data Sharing Statement